While there is currently no nomogram designed specifically to estimate EndoPredict® results in patients with ER-positive/HER2-negative breast carcinoma, several nomograms have been published for other genomic assays that are more widely used to assess relapse risk in this disease. Here, ERBB2 is linked to breast carcinoma.